Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study

Shen, 2015, Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling, Drug Discov Today, 20, 267, 10.1016/j.drudis.2014.10.002 Liu, 2010, Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer, Proc Natl Acad Sci U S A, 107, 6471, 10.1073/pnas.0908396107 Schmidt, 1984, Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins, J Biol Chem, 259, 10175, 10.1016/S0021-9258(18)90945-2 Agarwal, 2009, The emerging role of the RAB25 small GTPase in cancer, Traffic, 10, 1561, 10.1111/j.1600-0854.2009.00969.x Niessner, 2011, The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells, J Invest Dermatol, 131, 468, 10.1038/jid.2010.297 Bishop, 1995, Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells, J Biol Chem, 270, 30611, 10.1074/jbc.270.51.30611 Tamanoi, 2001, Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells, Cell Mol Life Sci, 58, 1636, 10.1007/PL00000802 Njoroge, 1997, J Med Chem, 40, 4290, 10.1021/jm970464g Lerner, 1995, Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes, J Biol Chem, 270, 26802, 10.1074/jbc.270.45.26802 End, 2001, Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro, Cancer Res, 61, 131 Mangues, 1998, Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice, Cancer Res, 58, 1253 Holstein, 2012, Is there a future for prenyltransferase inhibitors in cancer therapy, Curr Opin Pharmacol, 12, 704, 10.1016/j.coph.2012.06.013 Graaf, 2004, Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer, Cancer Treat Rev, 30, 609, 10.1016/j.ctrv.2004.06.010 Adjei, 2000, A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity, Cancer Res, 60, 1871 Liu, 2015, Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: a meta-analysis, Medicine (Baltimore), 94, e2014, 10.1097/MD.0000000000002014 van Beek E, 1999, Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates, Biochem Biophys Res Commun, 264, 108, 10.1006/bbrc.1999.1499 Ilyas, 2014, The effect of alendronate on proteome of hepatocellular carcinoma cell lines, Int J Proteomics, 2014, 10.1155/2014/532953 Pelaia, 2012, Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells, Cell Prolif, 45, 557, 10.1111/j.1365-2184.2012.00846.x Wojtkowiak, 2009, Working together: farnesyl transferase inhibitors and statins block protein prenylation, Mol Cell Pharmacol, 1, 1, 10.4255/mcpharmacol.09.01 Andela, 2002, Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis, Clin Orthop Relat Res, 228, 10.1097/00003086-200204000-00027 Andela, 2003, The mevalonate synthesis pathway as a therapeutic target in cancer, Clin Orthop Relat Res, S59, 10.1097/01.blo.0000093846.72468.66 Chou, 2011, The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development, Am J Cancer Res, 1, 925 Ilyas, 2015, Effects of 5′-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective, Mol Cell Biochem, 405, 53, 10.1007/s11010-015-2395-1 Mazzocca, 2003, Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines, Mol Pharmacol, 63, 159, 10.1124/mol.63.1.159 Housman, 2014, Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model, Antimicrob Agents Chemother, 58, 1365, 10.1128/AAC.02161-13 Abdel-Rahman, 2014, Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis, Expert Rev Anticancer Ther, 14, 1529, 10.1586/14737140.2014.953936 Yardley, 2013, Drug resistance and the role of combination chemotherapy in improving patient outcomes, Int J Breast Cancer, 2013, 10.1155/2013/137414 Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, 15, 943, 10.1016/S1470-2045(14)70314-6 Hu, 2003, Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor, Proteomics, 3, 1904, 10.1002/pmic.200300547 Csiki, 2006, Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer, Cancer Res, 66, 143, 10.1158/0008-5472.CAN-05-1357 Young, 2004, Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry, Cancer Res, 64, 4577, 10.1158/0008-5472.CAN-04-0222 Ai, 2006, Proteome analysis of hepatocellular carcinoma by laser capture microdissection, Proteomics, 6, 538, 10.1002/pmic.200500257 Tew, 2011, Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification, Drug Metab Rev, 43, 179, 10.3109/03602532.2011.552912 Geng, 2013, The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer, Diagn Pathol, 8, 198, 10.1186/1746-1596-8-198 van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967 Pratt, 2010, Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage, Exp Biol Med (Maywood), 235, 278, 10.1258/ebm.2009.009250 Arozarena, 2004, Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors, Mol Cell Biol, 24, 1516, 10.1128/MCB.24.4.1516-1530.2004 Sherwood, 2008, RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis, Mol Biol Cell, 19, 1772, 10.1091/mbc.e07-07-0652 Van Aelst L, 1997, Rho GTPases and signaling networks, Genes Dev, 11, 2295, 10.1101/gad.11.18.2295 Harhaj, 2011, Deubiquitinases in the regulation of NF-κB signaling, Cell Res, 21, 22, 10.1038/cr.2010.166